iCAD/ICAD

$1.68

2.44%
-
1D1W1MYTD1YMAX

About iCAD

iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.

Ticker

ICAD

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Dana Brown

Employees

67

Headquarters

Nashua, United States

iCAD Metrics

BasicAdvanced
$46M
Market cap
-
P/E ratio
-$0.09
EPS
1.55
Beta
-
Dividend rate
$46M
1.54512
$3.97
$1.14
200K
4.715
4.593
-11.7%
-16.02%
-14.93%
2.572
1.421
1.926
7.98%
47.13%
-16.45%

What the Analysts think about iCAD

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
187.5% upside
High $9.00
Low $2.50
$1.68
Current price
$4.83
Average price target

iCAD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-24.48% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4.9M
4.26%
Net income
-$1.2M
-160%
Profit margin
-24.48%
-157.53%

iCAD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.05%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.05
$0.05
-$0.05
-
Expected
-$0.11
-$0.09
-$0.05
-$0.06
-$0.07
Surprise
-36.36%
-44.44%
-193.75%
-21.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for iCAD stock?

iCAD (ICAD) has a market cap of $46M as of May 22, 2024.

What is the P/E ratio for iCAD stock?

The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of May 22, 2024.

Does iCAD stock pay dividends?

No, iCAD (ICAD) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next iCAD dividend payment date?

iCAD (ICAD) stock does not pay dividends to its shareholders.

What is the beta indicator for iCAD?

iCAD (ICAD) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the iCAD stock price target?

The target price for iCAD (ICAD) stock is $4.83, which is 196.32% above the current price of $1.63. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell iCAD stock

Buy or sell iCAD stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing